Atai Life Sciences Valued At More Than $3 Billion After IPO

Atai Life Sciences Valued At More Than $3 Billion After IPO

German psychedelic pharmaceutical company Atai Life Sciences is valued at more than $3 billion after its IPO listing on the Nasdaq.
Publicly-Traded Psychedelic Stocks

27 Publicly-Traded Psychedelic Stocks Investors Have Their Eyes On

These psychedelic stocks are all publicly trading. Take a look at the companies leading the psychedelic medicine revolution.
Psychedelic Business Spotlight: June 18, 2021

Psychedelic Business Spotlight: June 18, 2021

This week in psychedelic business news: Patent progress for biosynthetic psilocybin, psychedelics for brain health, and psychedelic and cannabis companies team up in the name of research.
Peter Thiel-Backed Atai Life Sciences Announces IPO With $2 Billion Valuation

Peter Thiel-Backed Atai Life Sciences Announces IPO With $2 Billion Valuation

Atai Life Sciences is the latest psychedelic company to announce plans to IPO. The Peter Thiel-backed biotech startup is valued at more than $2 billion.
Psychedelic Business Spotlight: June 11, 2021

Psychedelic Business Spotlight: June 11, 2021

This week in psychedelic business news: An all-female biotech company, psychedelic-assisted psychotherapy for COVID front-liners, and more.
Field Trip Health Trades on TSE

Field Trip Health Begins Trading on TSE, Sets Sights on Nasdaq

Psychedelic lifestyle brand Field Trip Health is now trading on the Toronto Stock Exchange under the symbol "FTRP".
GH Research Is Taking its Psychedelic 5-MeO-DMT 'Toad Venom' Public

GH Research Is Taking Psychedelic 5-MeO-DMT ‘Toad Venom’ Public

GH Research is taking its psychedelic 5-MeO-DMT public on the Nasdaq with an IPO valued at more than $100 million.
AI Tech-Led Psychedelic Therapy Platform Nue Life Health Raises $3.3 Million

AI Tech-Led Psychedelic Therapy Platform Nue Life Health Raises $3.3 Million

Nue Life Health is a new therapy platform relying on AI and music as well as psychedelics for customized healing.
Psychedelic Business News Spotlight

Psychedelic Business Spotlight: June 4, 2021

This week in psychedelic business: Mindset Pharma's new research, synthetic ibogaine, and the Western Hemisphere gets its first “smart shop.”
'PSY' Becomes First U.S.-Listed Psychedelic ETF

‘PSY’ Becomes First U.S.-Listed Psychedelic ETF

Defiance Next Gen Altered Experience ETF began trading Friday on the New York Stock Exchange under the symbol PSY.